Hegazy M G, Thysseril T J, Schlender K K, Reimann E M
Department of Biochemistry, Medical College of Ohio, Toledo 43699.
Arch Biochem Biophys. 1987 Nov 1;258(2):470-81. doi: 10.1016/0003-9861(87)90368-7.
A form of glycogen synthase kinase designated GSK-M3 was purified 4000-fold from rat skeletal muscle by phosphocellulose, Affi-Gel blue, Sephacryl S-300 and carboxymethyl-Sephadex column chromatography. Separation of GSK-M from the catalytic subunit of the cAMP-dependent protein kinase was facilitated by converting the catalytic subunit to the holoenzyme form by addition of the regulatory subunit prior to the gel filtration step. GSK-M had an apparent Mr 62,000 (based on gel filtration), an apparent Km of 11 microM for ATP, and an apparent Km of 4 microM for rat skeletal muscle glycogen synthase. The kinase had very little activity with 0.2 mM GTP as the phosphate donor. Kinase activity was not affected by the addition of cyclic nucleotides, EGTA, heparin, glucose 6-P, glycogen, or the heat-stable inhibitor of cAMP-dependent protein kinase. Phosphorylation of glycogen synthase from rat skeletal muscle by GSK-M reduced the activity ratio (activity in the absence of Glc-6-P/activity in the presence of Glc-6-P X 100) from 90 to 25% when approximately 1.2 mol of phosphate was incorporated per mole of glycogen synthase subunit. Phosphopeptide maps of glycogen synthase obtained after digestion with CNBr or trypsin showed that this kinase phosphorylated glycogen synthase in serine residues found in the peptides containing the sites known as site 2, which is located in the N-terminal CNBr peptide, and site 3, which is located in the C-terminal CNBr peptide of glycogen synthase. In addition to phosphorylating glycogen synthase, GSK-M phosphorylated inhibitor 2 and activated ATP-Mg-dependent protein phosphatase. Activation of the protein phosphatase by GSK-M was dependent on ATP and was virtually absent when ATP was replaced with GTP. GSK-M had minimal activity toward phosphorylase b, casein, phosvitin, and mixed histones. These data indicate that GSK-M, a major form of glycogen synthase kinase from rat skeletal muscle, differs from the known glycogen synthase kinases isolated from rabbit skeletal muscle.
一种名为GSK-M3的糖原合酶激酶通过磷酸纤维素、Affi-Gel蓝、Sephacryl S-300和羧甲基葡聚糖凝胶柱色谱法从大鼠骨骼肌中纯化了4000倍。在凝胶过滤步骤之前,通过添加调节亚基将cAMP依赖性蛋白激酶的催化亚基转化为全酶形式,从而促进了GSK-M与催化亚基的分离。GSK-M的表观分子量为62,000(基于凝胶过滤),对ATP的表观Km为11 microM,对大鼠骨骼肌糖原合酶的表观Km为4 microM。该激酶以0.2 mM GTP作为磷酸供体时活性很低。激酶活性不受环核苷酸、乙二醇双四乙酸、肝素、葡萄糖6-磷酸、糖原或cAMP依赖性蛋白激酶的热稳定抑制剂的影响。当每摩尔糖原合酶亚基掺入约1.2摩尔磷酸盐时,GSK-M对大鼠骨骼肌糖原合酶的磷酸化使活性比(无葡萄糖-6-磷酸时的活性/有葡萄糖-6-磷酸时的活性×100)从90%降至25%。用溴化氰或胰蛋白酶消化后得到的糖原合酶的磷酸肽图谱表明,该激酶在糖原合酶的丝氨酸残基上进行磷酸化,这些丝氨酸残基位于含有位点2的肽段中,位点2位于N端溴化氰肽段,以及位点3,位点3位于糖原合酶的C端溴化氰肽段中。除了磷酸化糖原合酶外,GSK-M还磷酸化抑制剂2并激活ATP-镁依赖性蛋白磷酸酶。GSK-M对蛋白磷酸酶的激活依赖于ATP,当ATP被GTP取代时几乎不存在这种激活作用。GSK-M对磷酸化酶b、酪蛋白、卵黄高磷蛋白和混合组蛋白的活性最小。这些数据表明,GSK-M是大鼠骨骼肌糖原合酶激酶的主要形式,与从兔骨骼肌中分离出的已知糖原合酶激酶不同。